Abiopharma

SERA PROGNOSTICS, INC. (SERA) Reports the reporting period Financial Results SERA PROGNOSTICS, INC. (SERA) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 20310
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 4175
  • expected in May. ▪European Expert Commentary on the PRIME Trial Published in The Journal of Maternal-Fetal & Neonatal Medicine: In March, expert commentary highlighted that current European preterm birth prevention strategies fail to identify most women who deliver preterm. They recognized that the PreTRM approach better aligns with existing European healthcare systems.•Commercial Progress: Launched third partnership program expanding physician education and access to PreTRM. This program is expected to reach over 350 providers across three states. In parallel, we are now engaged in active discussions with 13 payers across 15 states, reflecting our strategy to deepen relationships within a focused set of target markets.•Strong Presence Across Key Medical Meetings:▪American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in May: Participation included a dedicated product theater and targeted engagement with clinicians to discuss evidence generation and clinical implementation of PreTRM. ▪Society of Maternal-Fetal Medicine (SMFM) Annual Meeting in February: Highlighted key clinical evidence from PRIME study and engaged with maternal-fetal medicine specialists on PreTRM’s role in risk stratification and early intervention. We also engaged with SMFM leadership to discuss the PRIME study outcomes. •Continued Progress in Europe: Advancing toward CE marking with regulatory dossier preparation on track for mid‑year submission. Commercial readiness efforts are supported by ongoing clinical validation activities and engagement with European clinical and advisory stakeholders. •Cash Runway Extended Through 2029